Disclaimer: Whilst we always aim to provide accurate information, Recite Me uses machine translation so the translation may not be perfect and we can’t guarantee its accuracy. Myeloma UK accepts no liability for any inaccuracies resulting from the use of this translation tool. The information provided is not meant to replace the advice of your healthcare team. Find out more about this tool at reciteme.com
The Post ASH Highlights for Scotland meeting offers a comprehensive review of the most significant scientific and clinical updates from ASH 2024, with a focus on relevance to a Scottish audience. This full-day event is an opportunity for haematology professionals to stay informed about the latest updates and discuss their implications for clinical practice in Scotland.
The programme includes expert-led sessions on:
Acute leukaemia: Updates on AML, MDS, and ALL, including a discussion on transplant versus CAR-T.
Myeloma: Insights into newly diagnosed and relapsed refractory cases, as well as Scottish-specific considerations.
High-grade lymphomas: Advances in DLBCL treatments, CNS and T-cell lymphomas, and Hodgkin lymphoma.
Myeloproliferative neoplasms and CLL: Highlights of myelofibrosis, CML, low-grade lymphomas, and their Scottish implications.
A CAR-T workshop supported by industry will provide an interactive component, and coffee and lunch breaks offer opportunities to connect with colleagues.
